Krystal Biotech (NASDAQ:KRYS) Price Target Raised to $396.00

Krystal Biotech (NASDAQ:KRYS) had its price target raised by Bank of America from $364.00 to $396.00 in a research report released on Tuesday,Benzinga reports. They currently have a buy rating on the stock.

A number of other brokerages have also weighed in on KRYS. Jefferies Financial Group reissued a “buy” rating and issued a $474.00 target price on shares of Krystal Biotech in a research report on Monday. HC Wainwright upped their target price on shares of Krystal Biotech from $310.00 to $361.00 and gave the company a “buy” rating in a research note on Tuesday, June 16th. Wall Street Zen downgraded shares of Krystal Biotech from a “buy” rating to a “hold” rating in a report on Saturday, June 20th. TD Cowen lifted their price target on shares of Krystal Biotech from $306.00 to $403.00 and gave the stock a “buy” rating in a research note on Thursday, June 18th. Finally, Weiss Ratings cut shares of Krystal Biotech from a “buy (b)” rating to a “buy (b-)” rating in a report on Wednesday, July 1st. Ten investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, Krystal Biotech currently has a consensus rating of “Moderate Buy” and a consensus price target of $360.67.

Krystal Biotech Trading Down 2.4%

Shares of KRYS opened at $341.79 on Tuesday. The company has a market cap of $10.08 billion, a price-to-earnings ratio of 45.69 and a beta of 0.50. The business’s fifty day simple moving average is $330.40 and its two-hundred day simple moving average is $289.01. Krystal Biotech has a 12 month low of $130.50 and a 12 month high of $382.54.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings results on Monday, May 4th. The company reported $1.83 earnings per share for the quarter, topping the consensus estimate of $1.45 by $0.38. The firm had revenue of $116.36 million during the quarter, compared to analysts’ expectations of $112.11 million. Krystal Biotech had a return on equity of 19.25% and a net margin of 53.92%. As a group, research analysts forecast that Krystal Biotech will post 7.41 EPS for the current year.

Insider Activity

In other news, EVP John Charles Thomas sold 1,000 shares of Krystal Biotech stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $347.27, for a total transaction of $347,270.00. Following the transaction, the executive vice president directly owned 1,000 shares of the company’s stock, valued at $347,270. The trade was a 50.00% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $308.11, for a total value of $7,702,750.00. Following the transaction, the insider directly owned 1,378,155 shares in the company, valued at approximately $424,623,337.05. The trade was a 1.78% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 26,642 shares of company stock worth $8,243,923 in the last ninety days. Corporate insiders own 13.10% of the company’s stock.

Hedge Funds Weigh In On Krystal Biotech

Large investors have recently added to or reduced their stakes in the company. Sound Income Strategies LLC boosted its position in shares of Krystal Biotech by 1,270.0% in the fourth quarter. Sound Income Strategies LLC now owns 137 shares of the company’s stock worth $34,000 after purchasing an additional 127 shares during the period. Western Wealth Management LLC bought a new stake in shares of Krystal Biotech during the 1st quarter valued at $34,000. Greenline Wealth Management LLC bought a new stake in shares of Krystal Biotech during the 4th quarter valued at $34,000. Danske Bank A S purchased a new position in shares of Krystal Biotech during the 3rd quarter valued at $35,000. Finally, UMB Bank n.a. lifted its stake in shares of Krystal Biotech by 34.6% during the 4th quarter. UMB Bank n.a. now owns 144 shares of the company’s stock valued at $36,000 after buying an additional 37 shares in the last quarter. Hedge funds and other institutional investors own 86.29% of the company’s stock.

About Krystal Biotech

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.